Taho Pharmaceuticals (ROCO:6467) ROE % Adjusted to Book Value: -4.78% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6467 Taho Pharmaceuticals Ltd ROCO:6467
35 GF Score
Price NT$110.50
! 2 Warning Signs
View Full Analysis

What is Taho Pharmaceuticals ROE % Adjusted to Book Value?

Taho Pharmaceuticals ROCO:6467 -4.22% 35 ROE % Adjusted to Book Value is -4.78% as of Dec. 2025. GuruFocus rates ROCO:6467 with a GF Score™ of 35/100. The stock has 2 warning signs investors should review.

Taho Pharmaceuticals's ROE % for the quarter that ended in Dec. 2025 was -65.56%. Taho Pharmaceuticals's PB Ratio for the quarter that ended in Dec. 2025 was 13.72. Taho Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was -4.78%.

Taho Pharmaceuticals ROE % Adjusted to Book Value Related Terms

Taho Pharmaceuticals ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Taho Pharmaceuticals's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Taho Pharmaceuticals ROE % Adjusted to Book Value Chart

Taho Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only -16.89 -15.90 -135.09 -10.53 -3.33

Taho Pharmaceuticals Semi-Annual Data
Dec12 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -155.53 -155.12 -11.25 -4.91 -4.78

ROCO:6467 vs ZTS, UTHR: ROE % Adjusted to Book Value Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Taho Pharmaceuticals's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Taho Pharmaceuticals ROE % Adjusted to Book Value vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Taho Pharmaceuticals's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Taho Pharmaceuticals's ROE % Adjusted to Book Value falls into.


ROCO:6467
35GF Score
Taho Pharmaceuticals Ltd ROCO:6467
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Taho Pharmaceuticals ROE % Adjusted to Book Value Calculation

Taho Pharmaceuticals's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-45.62% / 13.72
=-3.33%

Taho Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-65.56% / 13.72
=-4.78%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -4.78% mean?
Taho Pharmaceuticals (ROCO:6467) has a ROE % Adjusted to Book Value of -4.78% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Taho Pharmaceuticals and its competitors.
Is Taho Pharmaceuticals' ROE % Adjusted to Book Value too high?
Taho Pharmaceuticals' current ROE % Adjusted to Book Value is -4.78%. Overall, Taho Pharmaceuticals has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Taho Pharmaceuticals' ROE % Adjusted to Book Value compare to ZTS and UTHR?
Taho Pharmaceuticals' ROE % Adjusted to Book Value of -4.78% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?
A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Taho Pharmaceuticals and its competitors. Taho Pharmaceuticals's current ROE % Adjusted to Book Value is -4.78%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taho Pharmaceuticals stock overvalued right now?
Taho Pharmaceuticals (ROCO:6467) has a current ROE % Adjusted to Book Value of -4.78%. The current ROE % Adjusted to Book Value is -4.78%. Taho Pharmaceuticals' overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Taho Pharmaceuticals (ROCO:6467), the current ROE % Adjusted to Book Value is -4.78% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Taho Pharmaceuticals Business Description

Address No. 550, Ruiguang Road, 3rd Floor, Neihu District, Taipei, TWN
Taho Pharmaceuticals Ltd is a Taiwan based company focused on identifying and developing new products that offer therapeutic options to patient populations that may be under served. It offers a transdermal delivery platform that allows the active ingredient to be absorbed by the skin and distributed through the bloodstream. Its transmucosal delivery system delivers the drug as a thin film, an evolution from tablets or capsules. The company is conducting research and development of multiple new drugs using two different drug delivery platform technologies: transdermal and transmucosal.
35GF Score

Get the complete analysis for ROCO:6467

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$110.50
Price